Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Therion Biologics Corporation
PANVAC-VF is an investigational cancer vaccine. The vaccine is based on the theory that the body can be taught to fight cancer by directing the immune system to attack specific targets found on cancer cells. These targets are called Tumor Associated Antigens, or TAA's. This trial will help determine if this vaccine can help fight cancer.
All patients will be required to sign an informed consent prior to the performance of any study-related procedures. Patients will be screened for eligibility within 14 days prior to their anticipated treatment start date (Day 0). Patients who meet all inclusion and exclusion criteria will be centrally randomized into the study and will receive a unique patient identification number and a treatment assignment. The ratio of active treatment to control is 1:1 (PANVAC-VF: best supportive care or palliative chemotherapy).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients \> 18 years of age who have been vaccinated against smallpox;
Histologically confirmed diagnosis of adenocarcinoma of the pancreas;
Patient has metastatic (Stage IV) disease;
ECOG performance status 0-1;
Failed a gemcitabine-containing chemotherapeutic regimen within 3 months of study entry.
You may not be if
Prior or concurrent immunotherapy for cancer;
Radiation therapy within 28 days prior to registration;
Systemic corticosteroid therapy (except inhaled or topical steroids) within 28 days of registration;
Significant cardiovascular abnormalities or diseases;
Known positive for HIV, hepatitis B and/or C;
Evidence of immunodeficiency or immune suppression.
Clareo Health | PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen
